• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Discontinuation of antiseizure medication at discharge after acute symptomatic neonatal seizures not associated with impaired neurodevelopment

byJake EngelandMichael Pratte
May 27, 2021
in Chronic Disease, Neurology, Pediatrics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. No significant difference in functional neurodevelopment was found at 24 months in infants who continued to take antiseizure medication (ASM) and those who discontinued ASM at time of hospital discharge following acute symptomatic neonatal seizures.

2. No significant differences were observed between cohorts in epilepsy development or gross motor function at 24 months.

Evidence Rating Level: 2 (Good)

Study Rundown: Antiseizure medications (ASMs) are often prescribed long-term for infants who suffered from acute symptomatic neonatal seizures due to concern for continued seizures and development of epilepsy; however, there is a lack of evidence to support ASM use to prevent epilepsy development, and there are significant potential adverse events from these drugs. This prospective, comparative effectiveness study compared functional neurodevelopment and risk of epilepsy at age 24 months in infants who discontinued versus maintained ASMs after discharge from neonatal seizure admission. Two-hundred seventy children (101 discontinued and 169 maintained ASMs) were evaluated at age 24 months, and there was no significant difference in the proportion of children with impaired functional neurodevelopment between groups. Furthermore, there were no significant differences between cohorts in the proportion of children who developed epilepsy or gross motor function measured at age 24 months. Overall, this study supports the notion that routine prolongation of ASMs after neonatal seizures may not be indicated in all infants. One limitation of this study, however, is that follow-up was limited to 24 months; therefore, the development of neurological impairments or epilepsy past that time point remains unknown.

Click to read the study in JAMA Neurology

Click to read an accompanying editorial in JAMA Neurology

Relevant Reading: Prophylactic phenobarbital administration after resolution of neonatal seizures: survey of current practice

RELATED REPORTS

Oxygenation strategies inconsequential in comatose survivors of cardiac arrest

Angiotensin receptor blockers may reduce the incidence of epilepsy in patients with hypertension

Prenatal exposure to high-dose folic acid associated with increased cancer risk in children of mothers with epilepsy

In-Depth [prospective cohort]: This comparative effectiveness study enrolled 303 infants with acute symptomatic seizures from 9 neonatal seizure registry (NSR) centres between July 2015 and March 2018. Neonates with transient reversible seizure causes were excluded. The primary outcome was functional neurodevelopment at age 24 months measured using the Warner Initial Developmental Evaluation of Adaptive and Functional Skills (WIDEA-FS). Secondary outcomes included epilepsy development and functional motor impairment. Two-hundred seventy children (mean 23.8 months; 147 male) were followed up at 24 months; 101 discontinued ASMs and 169 maintained ASMs post-discharge. Median difference in WIDEA-FS scores were 4 points (2%) higher among children who discontinued ASMs (median [IQR]: 165 [150-175] versus 161 [129-174]; p= 0.09). The proportion of children with impaired functional neurodevelopment at 24 months was 28% in those who discontinued ASMs and 37% in those who maintained ASMs (OR: 0.6; 95% CI: 0.4-1.1; p= 0.11). At 24 months, 11% of children who discontinued and 14% of children who maintained ASMs developed epilepsy (OR: 0.8; 95% CI: 0.4-1.6; p= 0.49); 13% who discontinued and 19% who maintained ASMs developed functional motor impairments (OR: 0.6; 95% CI: 0.3-1.3; p= 0.18). Propensity-adjusted analyses also demonstrated no significant differences between cohorts among all outcomes.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

 

 

 

Tags: epilepsyneonatalseizures
Previous Post

Fortification of breast milk with preterm formula powder noninferior compared to human milk fortifier in preterm neonates

Next Post

#VisualAbstract: Docetaxel, cisplatin, and cetuximab regimen is a safe alternative for patients with squamous cell carcinoma of the head and neck

RelatedReports

Wound surgical device found ineffective at infection control: ROSSINI Trial
Cardiology

Oxygenation strategies inconsequential in comatose survivors of cardiac arrest

October 26, 2022
Patient Basics: Seizure
Chronic Disease

Angiotensin receptor blockers may reduce the incidence of epilepsy in patients with hypertension

October 24, 2022
Paternal factors associated with short interpregnancy interval
Neurology

Prenatal exposure to high-dose folic acid associated with increased cancer risk in children of mothers with epilepsy

October 1, 2022
Digital imaging detects sight-threatening retinopathy of prematurity
Obstetrics

Half-dose antenatal betamethasone is inferior to full dose for preventing usage of neonatal surfactant

August 31, 2022
Next Post
#VisualAbstract: Docetaxel, cisplatin, and cetuximab regimen is a safe alternative for patients with squamous cell carcinoma of the head and neck

#VisualAbstract: Docetaxel, cisplatin, and cetuximab regimen is a safe alternative for patients with squamous cell carcinoma of the head and neck

Medical vaccine exemptions increase after elimination of nonmedical exemptions

Nationwide vaccination campaign with BNT162b2 (Pfizer–BioNTech) mRNA vaccine reports high immunogenicity across all age groups

Medical vaccine exemptions increase after elimination of nonmedical exemptions

Online modules for pediatricians on human papillomavirus communication strategies linked to increased HPV vaccination rates

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Faecal haemoglobin concentrations associated with mortality and cause of death in colorectal cancer screening
  • The Scan by 2 Minute Medicine®: Maternity Leave Left Out, Dry January, A Measles Resurgence, Dr. GPT
  • Former professional football players may be at greater risk of chronic disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options